Rheumnow Podcast ACR24 IL-17 Topic Panel Advancing Care with IL-17 Pathway Insights
Dec 5, 2024
Brian Joros, a faculty expert in rheumatology at Northwestern University, and Peter Nash from Griffith University in Brisbane join the discussion. They dive into breakthrough advancements in targeting the IL-17 pathway for rheumatic diseases. Insights from the ACR Annual Meeting reveal impressive MRI remission rates with bemikizumab for ankylosing spondylitis. The duo also explores innovations in psoriatic arthritis treatments, addressing effectiveness, safety, and the nuances of treatment switches during flare-ups, making a case for the evolution of IL-17 therapies.
AI Snips
Chapters
Transcript
Episode notes
Rising Star
- Philip Mease introduces Brian Joros as a rising star in rheumatology at Northwestern.
- He jokingly contrasts Joros' youth with his own seniority.
Kangaroo Encounter
- Philip Mease recounts a golfing story with Peter Nash in Brisbane, featuring kangaroos.
- He was photographed near a kangaroo that appeared puzzled by his presence on the course.
Bemikizumab's Impact
- Bemikizumab, a dual IL-17A and IL-17F inhibitor, shows promise in ankylosing spondylitis.
- MRI data reveals significant improvements in inflammation and structural damage after 16 and 52 weeks.